LifeStance Health Group, Inc.

Equities

LFST

US53228F1012

Healthcare Facilities & Services

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
5.85 USD -3.31% Intraday chart for LifeStance Health Group, Inc. -7.00% -25.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
LifeStance Health Appoints Teresa DeLuca to Its Board of Directors CI
Jefferies Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Buy Rating MT
Lifestance Health Group Insider Sold Shares Worth $923,391, According to a Recent SEC Filing MT
Goldman Sachs Adjusts Price Target on LifeStance Health to $9 From $8, Maintains Neutral Rating MT
UBS Adjusts LifeStance Health Group Price Target to $9 From $7, Maintains Neutral Rating MT
Barclays Adjusts LifeStance Health Group Price Target to $8 From $7, Maintains Underweight Rating MT
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care Stocks Softer Wednesday Afternoon MT
LifeStance Health Q4 Loss Narrows as Revenue Increases; Shares Rise MT
LifeStance Health Q4 Loss Narrows as Revenue Increases; Shares Rise MT
Transcript : LifeStance Health Group, Inc., Q4 2023 Earnings Call, Feb 28, 2024
LifeStance Health Group, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
LifeStance Health Group, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024 CI
LifeStance Health Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sector Update: Health Care Stocks Rise in Late Afternoon MT
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading MT
Sector Update: Health Care MT
LifeStance shares fall after Hindenburg takes short position RE
LifeStance Health Group Shares Fall After Hindenburg Research Report MT
LifeStance Health Group Shares Fall After Hindenburg Research Report MT
LifeStance Health Appoints Ujjwal Ramtekkar as Chief Medical Officer MT
Lifestance Appoints Ujjwal Ramtekkar as Chief Medical Officer, Effective January 22, 2024 CI
Goldman Sachs Adjusts Price Target on LifeStance Health to $8 From $9, Maintains Neutral Rating MT
JPMorgan Adjusts LifeStance Health Group's Price Target to $8 From $10, Maintains Neutral Rating MT
UBS Cuts LifeStance Health Group's Price Target to $7 From $10, Keeps Neutral Rating MT
Chart LifeStance Health Group, Inc.
More charts
LifeStance Health Group, Inc. is a mental healthcare company. The Company is focused on providing of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. Its clinicians provide services spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The Company treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. It uses evidence-based approaches to ensure effective treatment. The Company offers patients the ability to conduct a given visit with their clinician virtually. It has around 6,645 employed psychiatrists, APNs, psychologists, and therapists. It employs approximately 6,600 psychiatrists, advanced practice nurses, psychologists and therapists and operates across 33 states and more than 550 centers.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
5.85 USD
Average target price
8.786 USD
Spread / Average Target
+50.18%
Consensus